Company: BIAF
Filing Date: 2025-05-27
Form Type: 424B5
Source: 0001641172-25-012410
Chunk: 15

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-27
Form: 424B5
Chunk 15
---
 22, 2025, for aggregate gross proceeds of $5,801,000. The shares subject to the Sales Agreement with WallachBeth are being sold from time to time at various prices. An increase of $0.10 per share in the price at which the shares are sold from the assumed offering price per share shown in the table above, to $0.3753 per share, assuming all of our common stock in the aggregate amount of $5,801,000 during the term of the Sales Agreement with WallachBeth is sold at that price, would increase our pro forma as adjusted net tangible book value per share after the offering to $0.17 per share and would increase the dilution in net tangible book value per share to new investors in this offering to $0.2053 per share, after deducting commissions and estimated aggregate offering expenses payable by us. A decrease of $0.10 per share in the price at which the shares are sold from the assumed offering price per share shown in the table above, to $0.1753 per share, assuming all of our common stock in the aggregate amount of $5,801,000 during the term of the Sales Agreement with WallachBeth is sold at that price, would decrease our pro forma as adjusted net tangible book value per share after the offering to $0.12 per share and would decrease the dilution in net tangible book value per share to new investors in this offering to $0.0553 per share, after deducting commissions and estimated aggregate offering expenses payable by us. This information is supplied for illustrative purposes only.

The table and discussion above are based on 18,255,825 shares of common stock issued and outstanding as of March 31, 2025 and excludes as set forth below, as of that date:

| ● | 12,873,602                                                                                                                          
 shares of Common Stock issuable upon the exercise of outstanding warrants with a weighted average exercise price equal to $2.74 per 
 share;                                                                                                                              |
| ● | 304,125                                                                                                                             
 shares of Common Stock issuable upon the exercise of stock options issued under our equity incentive plans with a weighted average  
 exercise price equal to $6.95 per share; and                                                                                        |
| ● | 1,249,024                                                                                                                           
 shares of our Common Stock that are reserved for equity awards that may be granted under our 2024 Equity Incentive Plan.            |

To the extent that any outstanding options are exercised, new options or